Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

Written By Form Chicago

Authors: Ruben A Mesa, Stacie Hudgens , Lysbeth Floden , Claire N Harrison , Jeanne Palmer , Vikas Gupta, Donal P McLornan , Mary F McMullin , Jean-Jaques Kiladjian , Lynda Foltz , Uwe Platzbecker , M Laura Fox, Adam J Mead, David M Ross, Stephen T Oh, Andrew Perkins , Michael F Leahy, Samineh Deheshi, Rafe Donahue , Barbara J Klencke, Srdan Verstovsek 

DOI: 10.1002/cam4.5799

Form Chicago https://www.formchicago.com
Previous

Building a Community of Anthropological Practice: The Case of Anthropologists Working within the United States’ Largest Health Care System
Next

Best Practice Recommendations for Electronic Patient-Reported Outcome Dataset Structure and Standardization to Support Drug Development